The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.

The FDA cleared LabCorp's assay for quantitative determination of total cholesterol, high density lipoprotein cholesterol, triglycerides, and apolipoprotein B.

1Drop anticipates the platform will be capable of handling up to 64 clinical biomarkers, including indicators of cardiovascular diseases and many others.

A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.

The firm announced in October that had entered into an agreement with Jefferies to sell up to $50 million in shares from time to time.

A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.